Abstract:Background. Lymphocyte antigen 6 complex, locus E (LY6E) is abnormally expressed in several cancers and is associated with poor outcomes. However, the biological role of LY6E in colorectal cancer (CRC) remains largely unknown. Hence, we aimed to evaluate the expression levels, prognostic value, biological functions, and immune effects of LY6E via pan-cancer and CRC analyses using multiple databases. Methods. We analyzed the expression pattern of LY6E in various cancers. The prognostic value of LY6E expression was identified using the Kaplan-Meier analysis and the Cox regression models. We used gene set enrichment analysis (GSEA) to identify the potential functions of LY6E. Correlations between the LY6E expression and various factors, including LY6E methylation level, copy number variation (CNV), microsatellite instability (MSI), and immune checkpoint genes, were also analyzed. The levels of LY6E expression and immune infiltration were analyzed using CIBERSORT. We constructed a regulatory network that was in compliance with the competing endogenous RNA (ceRNA) hypothesis. A ceRNA expression-based nomogram was established. Real-time PCR (qRT-PCR) was applied to validate the expression of LY6E-related ceRNA in CRC cell lines. Results. LY6E is overexpressed in several tumor types, including CRC, and patients with high expression levels of LY6E have a poor prognosis. The Kaplan-Meier analysis and Cox regression analysis showed that LY6E could be considered a favorable prognostic factor in TCGA and GEO cohort. The results of GSEA showed that high LY6E expression levels were associated with immune-related pathways, such as those involved in antigen processing and presentation and the intestinal immune network for IgA production. Six methylation sites of LY6E that were associated with prognostic survival were screened. Moreover, the high levels of LY6E expression were correlated with copy number gain, microsatellite instability high, and immunotherapy response. The results of CIBERSORT analysis demonstrated that the LY6E expression levels were correlated with the infiltration of multiple immune cells, especially T cells. Then, we constructed a ceRNA network (LINC00963/miR-92a-3p/LY6E) and validated it using qRT-PCR. A predictive ceRNA-based nomogram was established and validated. Conclusion. The oncogenic LY6E may serve as a promising marker for the diagnosis and treatment of CRC.

Overexpression of Lymphocyte Antigen 6 Complex, Locus E in Gastric Cancer Promotes Cancer Cell Growth and Metastasis

Polypeptide N -acetylgalactosaminyltransferase-6 expression in gastric cancer.

Overexpressed Lncrna GATA6-AS1 Inhibits LNM and EMT Via FZD4 Through the Wnt/β-Catenin Signaling Pathway in GC.

eIF6 Promotes Gastric Cancer Proliferation and Invasion by Regulating Cell Cycle

E2F1 Induces LSINCT5 Transcriptional Activity and Promotes Gastric Cancer Progression by Affecting the Epithelial-Mesenchymal Transition

Multidimension Analysis of the Prognostic Value, Immune Regulatory Function, and Cerna Network of LY6E in Individuals with Colorectal Cancer

Expression and Clinical Significance of ECHS1 in Gastric Cancer.

The Keratin 17/YAP/IL6 Axis Contributes to E-cadherin Loss and Aggressiveness of Diffuse Gastric Cancer

CXCR 6 Predicts Poor Prognosis in Gastric Cancer and Promotes Tumor Metastasis Through Epithelial-Mesenchymal Transition

Prognostic Value of the Cancer Oncogene Kelch-like 6 in Gastric Cancer

Regulation of CD44v6 Expression in Gastric Carcinoma by the IL-6/STAT3 Signaling Pathway and Its Clinical Significance

lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p

Overexpression of Endothelial Cell Specific Molecule-1 (ESM-1) in Gastric Cancer

Lymphocyte antigen 6 family member E suppresses apoptosis and promotes pancreatic cancer growth and migration via Wnt/β-catenin pathway activation

S100a6 Overexpression is Associated with Poor Prognosis and is Epigenetically Up-Regulated in Gastric Cancer

The Polycomb Group Protein EZH2 Induces Epithelial–mesenchymal Transition and Pluripotent Phenotype of Gastric Cancer Cells by Binding to PTEN Promoter

ER Membrane Protein Complex Subunit 6 (EMC6) is a Novel Tumor Suppressor in Gastric Cancer.

CEACAM6 promotes tumor migration, invasion, and metastasis in gastric cancer.

Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D

LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis

Overexpression of Myosin VI Regulates Gastric Cancer Cell Progression.